

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: PTQ-0065

Inventors: Jonathan M. Lee

Serial No.: Not Yet Assigned

Filing Date: Herewith

Examiner: Not Yet Assigned


Group Art Unit: Not Yet Assigned

Title: EEF1A2 For Use in the Prognosis,
Diagnosis and Treatment of Cancer

"Express Mail" Label No. EV591080282US

Date of Deposit November 30, 2004

I hereby certify that this paper is being deposited with the
United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the Commissioner for Patents
Post Office Box 1450, Box PCT, Alexandria, VA 22313-1450

By 
Typed Name: Kathleen A. Tyrell, Reg. No. 38,350

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R.
§§1.97-1.98, information relating to the above-identified
application is hereby disclosed. Inclusion of information in
this statement is not to be construed as an admission that this
information is material as that term is defined in 37 C.F.R.
§1.56 (b).

(xx) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

10/516478

DT05 R PCT/PTO 30 NOV 2004


(xx) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

(xx) All listed references are in the English language with the exception of References AC and BB. An English Abstract is provided for Reference BB.

Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: November 30, 2004

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053
(856) 810-1515

10/516478

Docket No. PCT/PTO 30 NOV 2004

Sheet 01 of 02

Form PTO-1449 Modified		Docket No. PTQ-0065	Serial No. Not Yet Assigned
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Jonathan M. Lee	
U.S. Department of Commerce		Filing Date Herewith	Group Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Anand et al., "Gene encoding protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer", Nature Genetics 2002 31:301-305
	AB	Bischoff et al., "The Human Elongation Factor 1 A-2 Gene (EEF1A2):Complete Sequence and Characterization of Gene Structure and Promoter Activity", Genomics 2000 68:63-70
	AC	Cormier Patrick, "Facteurs de traduction:du contrôle de la synthèse des protéines au cycle cellulaire et à la tumorigenèse", Médecine/Sciences 2000 16:378-385
	AD	Edmonds et al., "Elongation factor-1 α is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma", Journal of Cell Science 1996 109:2705-2714
	AE	Gopalkrishnan et al., "Translational infidelity and human cancer:role of the PTI-1 oncogene", The International Journal of Biochemistry & Cell Biology 1999 31:151-162
	AF	Kuang et al., "Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line", Nucleic Acids Research 1998 26(4):1116-1123
	AG	Lund et al., "Assignment of Human Elongation Factor 1 α Genes:EEF1A Maps to Chromosome 6q14 and EEF1A2 to 20q13.3", Genomics 1996 36:359-361
EXAMINER		DATE CONSIDERED

10/516478
DTAS Rec'd PCT/PTO 30 NOV 2004

Sheet 02 of 02

<p>Form PTO-1449 Modified</p> <p>List of Patents and Publications Cited by Applicant (Use several sheets if necessary)</p> <p>U.S. Department of Commerce</p>	<p>Docket No. PTQ-0065</p>	<p>Serial No. Not Yet Assigned</p>
	<p>Applicant Jonathan M. Lee</p>	
	<p>Filing Date Herewith</p>	<p>Group Not Yet Assigned</p>

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	NO
	BA	WO 98/09655	12-3-98	PCT	X	
	BB	WO 00/71708	30-11-00	PCT	English Abstract	